Banco Latinoamericano de Comercio Exterior S.A. Apr 11

  • ID: 2091716
  • April 2011
  • Standard & Poors
1 of 3

Preferred creditor status in most countries in the region. Portfolio focused on trade finance 72% short term. Ample experience and expertise in the market and proactive management. Historical low level of NPL. Adequate core revenue generation but pressured profitability with volatile asset management business revenues. Vulnerability to economic cycle in the region. Geographic and depositor concentration. No lender of last resort. Standard & Poor's Ratings Services' ratings on Bladex reflect its adequate financial performance, strong market position with trade finance business, and the bank's fairly efficient and diversified operation that provides flexibility to its profitability. The short-term nature of its loan portfolio and Bladex's ability to recover in times of distress also support its ratings. The bank's exposure to speculative-grade...

Companies mentioned in this report are:
- Banco Latinoamericano de Comercio Exterior S.A.

Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Banco Latinoamericano de Comercio Exterior S.A.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our


Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.